Title:
IMMUNE MODULATION
Document Type and Number:
WIPO Patent Application WO/2019/139879
Kind Code:
A1
Abstract:
The disclosure relates to compositions, methods of use and making, and kits for immunomodulation. In some embodiments, the present invention also provides compositions including at least one antigen substantially co-localized with at least one adjuvant agent in a format selected from patch, capsule, tablet, gel, matrix, paste, reservoir, adhesive, liquid, suspension, lyophilized solid, liquid contained within one or more lumenal units, and combinations thereof, wherein one or both of the antigen and the adjuvant agent is a crude preparation, and wherein the composition is characterized in that administration to a subject in need thereof results in an immune response in the subject to the antigen.
More Like This:
| JP2009005709 | PRODUCTION METHOD OF T CELL EPITOPE OF MAJOR ALLERGEN FROM DERMATOPHAGOIDES (HOUSE DUST MITE) |
| WO/2022/101384 | SYSTEMS FOR BUCCAL RELEASE OF PROTEINS |
| WO/2008/143594 | HYPOALLERGENIC POLYPEPTIDES |
Inventors:
SOSIN HOWARD B (US)
CAPLAN MICHAEL J (US)
CAPLAN MICHAEL J (US)
Application Number:
PCT/US2019/012634
Publication Date:
July 18, 2019
Filing Date:
January 08, 2019
Export Citation:
Assignee:
N FOLD LLC (US)
International Classes:
A61K39/35; A61K39/39; A61P37/02
Domestic Patent References:
| WO2009051837A2 | 2009-04-23 | |||
| WO2007054279A2 | 2007-05-18 | |||
| WO1999066947A1 | 1999-12-29 |
Foreign References:
| US20170246294A1 | 2017-08-31 |
Other References:
XU ET AL.: "Recombinant Mycobacterium bovis BCG expressing the chimeric protein of antigen 85B and ESAT-6 enhances the Th1 cell -mediated response", CLIN VACCINE IMMUNOL, vol. 16, no. 8, 10 June 2009 (2009-06-10) - August 2009 (2009-08-01), pages 1121 - 1126, XP055623918
PFAAR ET AL.: "Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: a phase l/lla study", INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, vol. 154, no. 4, 25 October 2010 (2010-10-25) - 2011, pages 336 - 344, XP055623924
BIELINSKA ET AL.: "Immunomodulation of TH 2 biased immunity with mucosal administration of nanoemulsion adjuvant", VACCINE, vol. 34, no. 34, 23 June 2016 (2016-06-23), pages 4017 - 4024, XP029633377, doi:10.1016/j.vaccine.2016.06.043
KORSHOLM ET AL.: "T-helper 1 and T-helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injection", IMMUNOLOGY, vol. 129, no. 1, 14 July 2009 (2009-07-14), pages 75 - 86, XP055125482, doi:10.1111/j.1365-2567.2009.03164.x
See also references of EP 3737413A4
PFAAR ET AL.: "Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: a phase l/lla study", INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, vol. 154, no. 4, 25 October 2010 (2010-10-25) - 2011, pages 336 - 344, XP055623924
BIELINSKA ET AL.: "Immunomodulation of TH 2 biased immunity with mucosal administration of nanoemulsion adjuvant", VACCINE, vol. 34, no. 34, 23 June 2016 (2016-06-23), pages 4017 - 4024, XP029633377, doi:10.1016/j.vaccine.2016.06.043
KORSHOLM ET AL.: "T-helper 1 and T-helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injection", IMMUNOLOGY, vol. 129, no. 1, 14 July 2009 (2009-07-14), pages 75 - 86, XP055125482, doi:10.1111/j.1365-2567.2009.03164.x
See also references of EP 3737413A4
Attorney, Agent or Firm:
SMITH, Maria C. et al. (US)
Download PDF:
Previous Patent: DIRECTIONALLY FOCUSED ABLATION DEVICE
Next Patent: GAS OIL SEPARATION PLANT SYSTEMS AND METHODS FOR RAG LAYER TREATMENT
Next Patent: GAS OIL SEPARATION PLANT SYSTEMS AND METHODS FOR RAG LAYER TREATMENT